Neurotech International Limited (ASX:NTI)

-76.00% (1Y)

Market Cap	18.89M
Revenue (ttm)	80.48K
Net Income (ttm)	-11.79M
Shares Out	1.05B
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	289,696
Average Volume	606,355
Open	0.0190
Previous Close	0.0190
Day's Range	0.0170 - 0.0190
52-Week Range	0.0150 - 0.0930
Beta	0.43
RSI	46.21
Earnings Date	Jul 25, 2025

About Neurotech International

Neurotech International Limited, a clinical-stage biopharmaceutical development company, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company is focused on development and commercialization of NTI164 for multiple paediatric neurological disorders; and Mente, a clinically proven home therapy aimed at enhancing engagement and relaxation in autistic children exhibiting elevated delta band brain activity. It also engages in executing medical research projects; and developing techno...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2016
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: NTI

Financial Performance

In 2024, Neurotech International's revenue was 3.18 million, an increase of 166.00% compared to the previous year's 1.19 million. Losses were -5.07 million, -34.94% less than in 2023.